ID: MRFR/HC/6907-HCR | February 2021 | Region: Global | 100 pages
Global Migraine Drugs Market is expected to hold a value of USD 6.5 Billion by 2025 at a CAGR of 5.9%.
Migraine is a common neurovascular sickness that is characterized by tender headaches and is commonly associated with other neurological indications, such as nausea, vomiting, and painful sensitivity to lights and sounds. Migraine is more common in women than men, majorly due to the fluctuations in hormone levels. As of 2018, approximately 14.5% world’s population was suffering from different types of migraines, and 2% of the world’s population was suffering from chronic migraines.
The treatment of migraine headaches is eased by the administration of preventive medications, to avoid the migraine attacks and abortive medications to relieve the strong and periodic pain.
Migraine Drugs Market Influencer
The increasing prevalence of migraine is expected to contribute to the growth of the migraine drugs market during the forecast period.
By Treatment type
By Drug Class
Migraine Drugs Market Key Players
Frequently Asked Questions (FAQ) :
The global migraine drugs market is projected to reach a valuation of USD 6.5 BN by 2025.
The global migraine drugs market is projected to grow at approximately 5.9% CAGR during forecast period (2019-2025).
Rising R&D investments for the innovative drug discoveries for the treatment of the condition.
North America holds the largest share in the global migraine drugs market, followed by Europe and the Asia Pacific, respectively.
Alder Biopharmaceuticals, Inc. (US), Allergan Plc (Ireland), Pfizer Inc. (US), Merck & Co., Inc. (US), GlaxoSmithKline Plc (UK), Teva Pharmaceutical Industries Ltd (Israel), Johnson & Johnson Services, Inc. (US), AstraZeneca PLC (UK), Amgen Inc. (US), and Eli Lilly and Company eNeura Inc., are some of the major players operating in the migraine drugs market.
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.